Riskpilot← Back to searchSign inGet full accessGELMED AS
ASActiveOrg 917124086Ringveien 15, 8445 MelbuWholesale of pharmaceutical and medical goods · NACE 4646Est. 20161 employees
Revenue 2024
NOK 3,6M
+10% vs 2023
EBITDA margin
8.8%
+86% vs 2023
Equity ratio
25.1%
Financial strength
Net profit 2024
NOK 35K
-40% vs 2023
| Revenue | NOK 3,6M | +10% |
| EBITDA | NOK 313K | +86% |
| Net profit | NOK 35K | -40% |
| Total assets | NOK 1,3M | -11% |
| Equity | NOK 321K | +12% |
| Employees | 1 | — |
Legal name
GELMED AS
Org number
917124086
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
3. mai 2016
Share capital
NOK 30 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Salg av medisinsk utstyr, samt kursing innen førstehjelp og akuttmedisin. Drive salg av andre produkter/tjenester som naturlig hører sammen med dette, herunder rusmiddeltesting for ansatte i bedrifter, organisasjoner med mål om avdekking og forebygging av bruk av rusmidler. Delta i andre selskap med lignende virksomhet, og kjøp av aksjer eller på annen måte gjøre seg interessert i andre foretak. I tillegg drive turistnæring i nord-norge ved å tilby opplevelser, utfart, safari, samt annet som naturlig faller inn under dette.
Address
Ringveien 15, 8445 Melbu
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 1 346 | 1 715 | 2 200 | 3 250 | 3 574 |
| Staff expenses | −470 | −476 | −862 | −1 242 | −1 430 |
| EBITDA | −1 | 236 | 86 | 169 | 313 |
| Depreciation & amort. | −14 | −22 | −37 | −80 | −223 |
| EBIT | −15 | 214 | 49 | 89 | 90 |
| Net financials | −2 | −0 | −0 | −8 | −40 |
| Profit before tax | −17 | 214 | 49 | 81 | 50 |
| Tax | −0 | 33 | 27 | 23 | 15 |
| Net profit | −17 | 181 | 22 | 58 | 35 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 147 | 377 | 432 | 1 431 | 1 279 |
| Equity | 25 | 206 | 228 | 286 | 321 |
| Long-term debt | 0 | 2 | 1 | 517 | 555 |
| Short-term debt | 123 | 168 | 203 | 627 | 403 |
| Total debt | 123 | 171 | 205 | 1 144 | 958 |
EBITDA margin
8.8%
This company
15.8%
Market median
-44% vs market
20202024
Equity ratio
25.1%
This company
38.2%
Market median
-34% vs market
20202024
Return on equity
10.9%
This company
18.4%
Market median
+41% vs market
20202024
Net profit margin
1.0%
This company
8.1%
Market median
-88% vs market
20202024
Asset turnover
2.79×
This company
1.12×
Market median
+149% vs market
20202024
Debt / equity
2.98×
This company
0.62×
Market median
-381% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
GE Chief Executive Officer | Chief Executive Officer | 2016 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Board of Directors | 2016 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of GELMED AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Geir Einar Larsen | Chief Executive Officer | 0 companies |
| Rune Steinum | Board of Directors | 0 companies |